BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29975246)

  • 21. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
    Xu Y; Bai QM; Yang F; Zhu XL; Lu YM; Zhang J; Yang WT; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):545-9. PubMed ID: 27510780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
    Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
    J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Assessment of HER2 Gene Status by Fluorescence In Situ Hybridization in Invasive Breast Carcinomas With Equivocal HER2 Immunostaining: Experience From a Single Institution.
    Efared B; Sidibé IS; Gamrani S; El Otmani I; Erregad F; Hammas N; Bennis S; Chbani L; El Fatemi H
    Int J Surg Pathol; 2018 Oct; 26(7):593-599. PubMed ID: 29629604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
    Ragazzi M; Bisagni A; Gasparini E; Kuhn E; Bassano C; Tamagnini I; Foroni M; Bortesi M; Falco G; Ferrari G; Braglia L; Savoldi L; Bologna A; Di Cicilia R; Bisagni G; Gardini G
    Breast; 2017 Aug; 34():65-72. PubMed ID: 28521178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.
    Vogel UF
    Diagn Pathol; 2010 Jul; 5():50. PubMed ID: 20670419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category.
    Pasricha S; Gupta G; Garg R; Sharma A; Gandhi JS; Durga G; Kamboj M; Grover S; Mehta A
    Breast J; 2018 Jul; 24(4):468-472. PubMed ID: 29251392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
    Calhoun BC; Collins LC
    Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay.
    Desai NV; Torous V; Parker J; Auman JT; Rosson GB; Cruz C; Perou CM; Schnitt SJ; Tung N
    Breast Cancer Res; 2018 Jul; 20(1):75. PubMed ID: 29996866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.
    Pekar G; Kasselaki I; Pekar-Lukacs A; Dekany C; Hellberg D; Tot T
    Histopathology; 2019 Jan; 74(2):300-310. PubMed ID: 30113715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
    Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
    Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
    Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
    Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
    Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
    Curado M; Caramelo AS; Eloy C; Polónia A
    Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.